Primary hypersomnias of central origin

Seminars in Neurology

Volumn 29, Issue 4, 2009, Pages 354-367

  Frenette, Eric ^a   Kushida, Clete A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cataplexy; Idiopathic hypersomnia; KleineLevin syndrome; Narcolepsy; Primary hypersomnia

Indexed keywords

AMANTADINE; AMPHETAMINE; ARMODAFINIL; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LAMOTRIGINE; LEUKOCYTE ANTIGEN; LITHIUM; MELATONIN; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; OREXIN; OXYBATE SODIUM; PEMOLINE; PLACEBO; PROTRIPTYLINE; VALPROIC ACID; VENLAFAXINE;

ANOREXIA; BEDTIME DOSAGE; BLOOD PRESSURE; CATAPLEXY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ENURESIS; EPIDEMIOLOGICAL DATA; EPWORTH SLEEPINESS SCALE; FEVER; FOOD AND DRUG ADMINISTRATION; GROUPS BY AGE; HEART PALPITATION; HLA SYSTEM; HUMAN; HYPERSOMNIA; HYPNAGOGIC HALLUCINATION; IMMUNOTHERAPY; INFECTION; INSOMNIA; LEG MOVEMENT; LOW DRUG DOSE; MORNING DOSAGE; NARCOLEPSY; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASOMNIA; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RECURRENT DISEASE; REM SLEEP; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SOMNOLENCE; TACHYCARDIA; WEIGHT REDUCTION; XEROSTOMIA;

CATAPLEXY; DIAGNOSIS, DIFFERENTIAL; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; KLEINE-LEVIN SYNDROME; NARCOLEPSY;

EID: 70449436534     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0029-1237114     Document Type: Review

References (104)

1. Schenck C H., Bassetti C L., Arnulf I, Mignot E. English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gélineau in the late 19th century, with commentary. J Clin Sleep Med 2007 3 (3) 301-311
2. Adie W J. Idiopathic narcolepsy: a disease sui generis; with remarks on the mechanism of sleep. Brain 1926 49 257-306
3. Prinzmetal M, Bloomberg W. The use of Benzedrine for the treatment of narcolepsy. JAMA 1935 105 2051-2054
4. Billiard M, Besset A, Montplaisir J et al. Modafinil: a double-blind multicentric study. Sleep 1994 17 (8, Suppl) S107-S112
5. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960 21 704-706
6. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979 6 (1) 1-6
7. U.S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002 25 (1) 42-49
8. Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984 24 (5) 316-319
9. Mignot E, Lin X, Arrigoni J et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans. Sleep 1994 17 (8, Suppl) S60-S67
10. de Lecea L, Kilduff T S., Peyron C et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998 95 (1) 322-327
11. Nishino S, Ripley B, Overeem S, Lammers G J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000 355 (9197) 39-40
12. Peyron C, Faraco J, Rogers W et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000 6 (9) 991-997
13. Thannickal T C., Moore R Y., Nienhuis R et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000 27 (3) 469-474
14. Yoss R E., Daly D D. Treatment of narcolepsy with ritalin. Neurology 1959 9 (3) 171-173
15. Vogel G. Studies in psychophysiology of dreams. III. The dream of narcolepsy. Arch Gen Psychiatry 1960 3 421-428
16. Xyrem approved for muscle problems in narcolepsy. FDA Consum 2002 36 (5) 7
17. Ohayon M M., Priest R G., Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002 58 (12) 1826-1833
18. Silber M H., Krahn L E., Olson E J., Pankratz V S. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002 25 (2) 197-202
19. Dauvilliers Y, Montplaisir J, Molinari N et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001 57 (11) 2029-2033
20. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998 50 (2, Suppl 1) S16-S22
21. Guilleminault C, Dement WC, Passouant P Narcolepsy. New York Spectrum Publications 1976
22. Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003 114 (11) 2000-2017
23. Bassetti CL, Billiard M, Mignot E Narcolepsy and Hypersomnia. Lung Biology in Health and Disease. Vol. 220. New York Informa Healthcare 2007
24. Hishikawa Y, Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Adv Neurol 1995 67 245-271
25. Takeuchi T, Miyasita A, Inugami M, Sasaki Y, Fukuda K. Laboratory documented hallucination during sleep-onset REM period in a normal subject. Percept Mot Skills 1994 78 (3 Pt 1) 979-985
26. Szucs A, Janszky J, Holló A, Migléczi G, Halász P. Misleading hallucinations in unrecognized narcolepsy. Acta Psychiatr Scand 2003 108 (4) 314-316, 316317
27. Plazzi G, Serra L, Ferri R. Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 2008 12 (2) 109-128
28. Sturzenegger C, Bassetti C L. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004 13 (4) 395-406
29. Aldrich M S. Diagnostic aspects of narcolepsy. Neurology 1998 50 (2, Suppl 1) S2-S7
30. Dauvilliers Y, Pennestri M H., Petit D, Dang-Vu T, Lavigne G, Montplaisir J. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res 2007 16 (3) 333-339
31. Nightingale S, Orgill J C., Ebrahim I O., de Lacy S F., Agrawal S, Williams A J. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med 2005 6 (3) 253-258
32. Dauvilliers Y, Rompré S, Gagnon J F., Vendette M, Petit D, Montplaisir J. REM sleep characteristics in narcolepsy and REM sleep behavior disorder. Sleep 2007 30 (7) 844-849 (Pubitemid 47041387)
33. Baker T L., Guilleminault C, Nino-Murcia G, Dement W C. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep 1986 9 (1 Pt 2) 232-242
34. Mignot E, Hayduk R, Black J, Grumet F C., Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997 20 (11) 1012-1020 (Pubitemid 28042450)
35. Nishino S. The hypothalamic peptidergic system, hypocretin/orexin and vigilance control. Neuropeptides 2007 41 (3) 117-133
36. Guilleminault C, Gelb M. Clinical aspects and features of cataplexy. Adv Neurol 1995 67 65-77
37. Rubboli G, d'Orsi G, Zaniboni A et al. A video-polygraphic analysis of the cataplectic attack. Clin Neurophysiol 2000 111 (Suppl 2) S120-S128
38. Overeem S, Reijntjes R, Huyser W, Lammers G J., van Dijk J G. Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia. J Sleep Res 2004 13 (3) 257-264
39. Overeem S, Lammers G J., van Dijk J G. Cataplexy: tonic immobility rather than REM-sleep atonia? Sleep Med 2002 3 (6) 471-477
40. Johns M W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991 14 (6) 540-545
41. Richardson G S., Carskadon M A., Flagg W, Van den Hoed J, Dement W C., Mitler M M. Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects. Electroencephalogr Clin Neurophysiol 1978 45 (5) 621-627
42. Littner M R., Kushida C, Wise M et al, Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005 28 (1) 113-121
43. Mignot E, Lammers G J., Ripley B et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002 59 (10) 1553-1562
44. American Sleep Disorders Association, Diagnostic Classification Steering Committee. International Classification of Sleep Disorders: Diagnostic and Coding Manual, ICSD-R. Westchester, IL American Academy of Sleep Medicine 2005
45. U.S. Food and Drug Administration (FDA). InfoSheets. 2005. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/pemolineHCP.pdf Accessed September 20, 2008
46. Mitler M M., Hajdukovic R, Erman M K. Treatment of narcolepsy with methamphetamine. Sleep 1993 16 (4) 306-317
47. Kuczenski R, Segal D S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997 68 (5) 2032-2037 Erratum in: J Neurochem 1997;69(3):1332 (Pubitemid 27176139)
48. Mitler M M., Shafor R, Hajdukovich R, Timms R M., Browman C P. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986 9 (1 Pt 2) 260-264
49. Wisor J P., Nishino S, Sora I, Uhl G H., Mignot E, Edgar D M. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001 21 (5) 1787-1794
50. Qu W M., Huang Z L., Xu X H., Matsumoto N, Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 2008 28 (34) 8462-8469
51. Wisor J P., Eriksson K S. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005 132 (4) 1027-1034
52. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998 43 (1) 88-97
53. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000 54 (5) 1166-1175
54. Moldofsky H, Broughton R J., Hill J D. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000 1 (2) 109-116
55. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005 6 (5) 415-421
56. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003 26 (1) 31-35
57. Black J, Houghton W C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006 29 (7) 939-946
58. Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004 27 (7) 1327-1334
59. Van Cauter E, Plat L, Scharf M B. et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J Clin Invest 1997 100 (3) 745-753
60. Schmidt H S., Clark R W., Hyman P R. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 1977 134 (2) 183-185
61. Schachter M, Parkes J D. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 1980 43 (2) 171-174
62. Vignatelli L, D'Alessandro R, Candelise L. Antidepressant drugs for narcolepsy. Cochrane Database Syst Rev 2008 (1) CD003724
63. Morgenthaler T I., Kapur V K., Brown T et al, Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007 30 (12) 1705-1711
64. Harsh J R., Hayduk R, Rosenberg R et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006 22 (4) 761-774
65. Lin J S. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 2000 4 (5) 471-503
66. Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003 26 (8) 953-959
67. Hanson L R., Martinez P M., Taheri S et al. Intranasal administration of hypocretin-1 (orexin A) bypasses the blood-brain barrier and targets the brain:a new strategy for the treatment of narcolepsy. Drug Delivery Technol 2004 4 66-71
68. Arias-Carrión O, Murillo-Rodriguez E, Xu M, Blanco-Centurion C, Drucker-Colín R, Shiromani P J. Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004 27 (8) 1465-1470
69. Arias-Carrión O, Drucker-Colín R, Murillo-Rodríguez E. Survival rates through time of hypocretin grafted neurons within their projection site. Neurosci Lett 2006 404 (1-2) 93-97
70. Mieda M, Willie J T., Hara J, Sinton C M., Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004 101 (13) 4649-4654
71. Hecht M, Lin L, Kushida C A. et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003 26 (7) 809-810
72. Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005 58 (3) 489-490
73. Lecendreux M, Maret S, Bassetti C, Mouren M C., Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003 12 (4) 347-348
74. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004 56 (6) 905-908
75. Zuberi S M., Mignot E, Ling L et al. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res 2004 13 (Suppl 1) 828
76. Fronczek R, Verschuuren J, Lammers G J. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 2007 254 (11) 1607-1608
77. Valko P O., Khatami R, Baumann C R., Bassetti C L. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol 2008 255 (12) 1900-1903
78. Fronczek R, Overeem S, Lammers G J., van Dijk J G., Van Someren E J. Altered skin-temperature regulation in narcolepsy relates to sleep propensity. Sleep 2006 29 (11) 1444-1449
79. Fronczek R, Raymann R JEM, Romeijn N et al. Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy. Sleep 2008 31 (2) 233-240
80. Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with sleep drunkenness Arch Gen Psychiatry 1972 26 (5) 456-462
81. Aldrich M S. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996 46 (2) 393-401
82. Bassetti C, Aldrich M S. Idiopathic hypersomnia. A series of 42 patients. Brain 1997 120 (Pt 8) 1423-1435
83. Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev 2001 5 (5) 349-358
84. Anderson K N., Pilsworth S, Sharples L D., Smith I E., Shneerson J M. Idiopathic hypersomnia: a study of 77 cases. Sleep 2007 30 (10) 1274-1281
85. Heier M S., Evsiukova T, Vilming S, Gjerstad M D., Schrader H, Gautvik K. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 2007 30 (8) 969-973
86. Bové A, Culebras A, Moore J T., Westlake R E. Relationship between sleep spindles and hypersomnia. Sleep 1994 17 (5) 449-455
87. Sforza E, Gaudreau H, Petit D, Montplaisir J. Homeostatic sleep regulation in patients with idiopathic hypersomnia. Clin Neurophysiol 2000 111 (2) 277-282
88. Nevsímalová S, Blazejová K, Illnerová H et al. A contribution to pathophysiology of idiopathic hypersomnia. Suppl Clin Neurophysiol 2000 53 366-370
89. Bruck D, Parkes J D. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data. J Neurol Neurosurg Psychiatry 1996 60 (5) 576-578 (Pubitemid 26147902)
90. Montplaisir J, Fantini L. Idiopathic hypersomnia: a diagnostic dilemma. A commentary of Idiopathic Hypersomnia (M. Billiard and Y. Dauvilliers). Sleep Med Rev 2001 5 (5) 361-362
91. Critchley M, Hoffman H. The syndrome of periodic somnolence and morbid hunger (KleineLevin syndrome). BMJ 1942 1 137-139
92. Arnulf I, Zeitzer J M., File J, Farber N, Mignot E. KleineLevin syndrome: a systematic review of 186 cases in the literature. Brain 2005 128 (Pt 12) 2763-2776
93. Arnulf I, Lin L, Gadoth N et al. Kleine-Levin syndrome: a systematic study of 108 patients. Ann Neurol 2008 63 (4) 482-493
94. Huang Y S., Lin Y H., Guilleminault C. Polysomnography in KleineLevin syndrome. Neurology 2008 70 (10) 795-801
95. Gadoth N, Kesler A, Vainstein G, Peled R, Lavie P. Clinical and polysomnographic characteristics of 34 patients with KleineLevin syndrome. J Sleep Res 2001 10 (4) 337-341
96. Dauvilliers Y, Mayer G, Lecendreux M et al. Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses. Neurology 2002 59 (11) 1739-1745
97. Huang Y S., Guilleminault C, Kao P F., Liu F Y. SPECT findings in the Kleine-Levin syndrome. Sleep 2005 28 (8) 955-960
98. Podestá C, Ferreras M, Mozzi M, Bassetti C, Dauvilliers Y, Billiard M. Kleine-Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements. Sleep Med 2006 7 (8) 649-651
99. Carpenter S, Yassa R, Ochs R. A pathologic basis for Kleine-Levin syndrome. Arch Neurol 1982 39 (1) 25-28
100. Koerber R K., Torkelson R, Haven G, Donaldson J, Cohen S M., Case M. Increased cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in Kleine-Levin syndrome. Neurology 1984 34 (12) 1597-1600
101. Muratori F, Bertini N, Masi G. Efficacy of lithium treatment in Kleine-Levin syndrome. Eur Psychiatry 2002 17 (4) 232-233
102. Surges R, Walker M C. A case of late-onset Kleine-Levin syndrome responding to lamotrigine. Sleep Med 2009 10 (3) 394
103. Crumley F E. Valproic acid for Kleine-Levin syndrome. J Am Acad Child Adolesc Psychiatry 1997 36 (7) 868-869
104. Kryger MH, Roth T, Dement WC Principles and Practice of Sleep Medicine. 4th ed. Amsterdam Elsevier Available at: http://www.sleepmedtext.com/content/ default.cfm Accessed November 12, 2008